共查询到4条相似文献,搜索用时 0 毫秒
1.
Clinical outcomes and histological findings of patients with advanced metastatic germ cell tumors undergoing post‐chemotherapy resection of retroperitoneal lymph nodes and residual extraretroperitoneal masses
下载免费PDF全文
![点击此处可从《International journal of urology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Terukazu Nakamura Masakatsu Oishi Takashi Ueda Atsuko Fujihara Hiroyuki Nakanishi Kazumi Kamoi Yoshio Naya Fumiya Hongo Koji Okihara Tsuneharu Miki 《International journal of urology》2015,22(7):663-668
2.
3.
Zhao-Jie Lv Song Wu Pei Dong Kai Yao Yin-Yin He Yao-Ting Gui Fang-Jian Zhou Zhuo-Wei Liu Zhi-Ming Cai 《Asian journal of andrology》2013,15(4):558-563
This study assesses the long-term outcomes in Han Chinese patients with clinical stage I non-seminomatous germ cell testicular cancer (CSI NSGCT) treated with surveillance, retroperitoneal lymph node dissection (RPLND) and adjuvant chemotherapy. We retrospectively evaluated 89 patients with a mean age of 26.5 years. After orchiectomy, 37 patients were treated with surveillance, 34 underwent RPLND and 18 were managed with chemotherapy. The overall survival rate, the recurrence-free survival rate and the risk factors were evaluated. The median follow-up length was 92 months (range: 6–149 months). Thirteen of the 89 patients (14.6%) had relapses, and one died by the evaluation date. The overall survival rate was 98.9%. The cumulative 4-year recurrence-free rates were 80.2%, 92.0% and 100% for the surveillance, RPLND and chemotherapy groups, respectively. The disease-free period tended to be briefer in patients with a history of cryptorchidism and those with stage Is. Therefore, surveillance, RPLND and adjuvant chemotherapy might be reliable strategies in compliant patients with CSI NSGCT. Surveillance should be recommended for patients with the lowest recurrence rate, especially those without lymphovascular invasion. This study might aid the establishment of a standard therapy for CSI NSGCT in China. 相似文献
4.
Lara Kremer Melanie von Brandenstein Maike Wittersheim Barbara Koeditz Pia Paffenholz Martin Hellmich David Pfister Axel Heidenreich Tim Nestler 《Translational andrology and urology》2021,10(4):1647
BackgroundTo identify a combination of microRNAs (miRNA) to differentiate between viable tumor (V) or teratoma (T) and necrosis/fibrosis (N) in pcRPLND specimens of metastatic germ cell tumor (GCT) patients with residual masses ≥1 cm after chemotherapy. Biomarker guided therapy could reduce overtreatment with pcRPLND in patients with only N.MethodsWe selected 48 metastatic GCT patients who had undergone pcRPLND. V, pure T and N was shown in the resected tissue of 16 patients, respectively. Of these areas total RNA was isolated and miRNA expression was analyzed for miR-371a-3p, 375-3p, and 375-5p using qPCR. ROC analysis was performed for each miRNA and for all combinations in order to determine the discriminatory capacity of V and T vs. N.ResultsOn comparing V vs. N miR-371a-3p achieved the highest fold change (FC) of 31.1 (P=0.023) while for T vs. N miR-375-5p performed best (FC 64.2; P<0.001). Likewise, the most accurate AUC for V was 0.75 using miR-371a-3p, for T 0.80 using miR-375-5p. Combining the best performing miRNAs for V and T resulted in an AUC of 0.94 with a sensitivity of 93.75, specificity of 93.75, PPV of 96.8 and NPV of 83.3.ConclusionsBy combining miR-371a-3p and miR-375-5p in pcRPLND tissue samples V and T could be distinguished from necrosis/fibrosis with great accuracy. This combination of miRNAs might serve as new biomarker in the future, in order to spare miRNA-negative patients from pcRPLND. However, further studies analyzing patient’s serum are needed to confirm the clinical impact of these biomarkers. 相似文献